IntoCell
Business Services · South Korea · 11-50 Employees
View Company Info for Free
Overview
Headquarters
101 Shinildong-ro Daedeok-gu, Daejeon, 3...Phone Number
+82 427160083Website
www.intocell.co.krRevenue
$11 MillionIndustry
About IntoCell
IntoCell is a Korea-based biotechnology company dedicated to the development and commercialisation of novel ADC platform technologies comprising scaffold moiety, ligands, toxins, linkers and conjugation methods. In addition to its OHPAS linker, the company has also successfully developed and tested its own proprietary benzodiazepines (BD) to overcome the challenges of existing BD toxins including their lack of conjugatable functional groups and their poor aqueous solubility. IntoCell is currently seeking research and development partners interested in licensing its ADC platform technologies. It is open to discussing exploratory pilot and feasibility studies for its cleavage chemistry focused linker technology and its novel benzodiazepine payloads.Explore more
IntoCell Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
IntoCell Tech Stack
A closer look at the technologies used by IntoCell
See more technologies
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding IntoCell
Sign Up For FreeTo access detailed company insights
IntoCell is a Korea-based biotechnology company dedicated to the development and commercialisation of novel ADC platform technologies comprising scaffold moiety, ligands, toxins, linkers and conjugation methods. In addition to its OHPAS linker, the company has also successfully developed and tested its own proprietary benzodiazepines (BD) to overco... Read More
